Navigation Links
Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
Date:8/6/2008

portant biological activity. This dosing regimen is being used in DEFEND. For more information on DEFEND, please see http://www.DefendAgainstDiabetes.com.

Tolerx Collaboration with GlaxoSmithKline

In October 2007, Tolerx and GlaxoSmithKline (GSK) entered into a global alliance to develop and commercialize otelixizumab in numerous indications, including type 1 diabetes. Under the terms of the agreement, Tolerx is responsible for conducting the Phase 3 clinical program for type 1 diabetes in the US and if successful, for submitting the biologics license application (BLA) to the FDA. Tolerx has the option to co-promote otelixizumab in type 1 diabetes in the US with GSK while GSK has exclusive rights to develop and commercialize otelixizumab in all other indications worldwide, including pediatric type 1 diabetes.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. Tolerx currently has two antibodies in clinical development: otelixizumab and a modified version of TRX1, MTRX1011A. MTRX1011A is a humanized anti-CD4 monoclonal antibody being developed in collaboration with Genentech, Inc. Tolerx is also engaged in preclinical development of new monoclonal antibody product candidates that engage the body's immune system and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the treatment of cancer, chronic viral diseases, and as an adjunct to vaccines. For more information, please visit http://www.tolerx.com.

Tolerx Forward-Looking Statements

This press release contains certain statements that are preceded by, followed by, or that include the words "will evaluate," "will," "look forward," "believe," and "has the potential to," or similar expressions or the negation thereof. Such stateme
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014 Clementia Pharmaceuticals, ... Agency (EMA) has granted Orphan Medicinal Product ... candidate, for the treatment of fibrodysplasia ossificans ... disabling genetic disease characterized by painful, recurrent ... new abnormal bone formation. This process, known ...
(Date:11/21/2014)... Ontario , Nov. 20, 2014  RedRick ... mounting solutions and reading room environment guidance, has ... newest musculoskeletal radiology reading room, which may also ... designs at Penn Medicine. "In ... the American College of Radiology,s Imaging 3.0 ™ ...
(Date:11/21/2014)...   Coqui RadioPharmaceuticals Corp. , a medical isotope ... of Molybdenum-99 (Mo-99), is proud to announce it has ... design its Medical Isotope Production Facility (MIPF) in ... isotope of Technetium-99, which is used in 80 percent ... legislation making it a national priority to produce Mo-99, ...
Breaking Medicine Technology:Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... Del., May 14, 2012  Synchrogenix Information Strategies Inc., a ... to announce the addition of a new office in ... Synchrogenix CEO, Ellen Barrosse, has appointed Bengt Olsson ... company,s newest office, located in Stockholm, Sweden.  With more ...
... 14, 2012  Eli Lilly and Company (NYSE: LLY ... its clinical oncology pipeline during the 48th Annual Meeting of ... Ill. from June 1 – 5, 2012. ... late-stage development to treat various types of cancer. The company ...
Cached Medicine Technology:Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 2Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 3Lilly Oncology To Disclose New Pipeline Data At ASCO 2012 4
(Date:11/23/2014)... has recently announced that its Special Friday Shoes sales, ... offer will provide ladies many gorgeous shoes at greatly discounted ... women’s dresses retailers, and its shoes include many models in ... that day: Everything at Tbdress.com is up to 90% off. ... People can use the following coupon codes as well: , ...
(Date:11/23/2014)... 21, 2014 (HealthDay News) -- Close friends have more ... group does, a new study says. "We,ve ... have an influence on individual alcohol use, but there ... peer group and the friend group,s influence on those ... School of Public Health, said in a university news ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... 23, 2014 More than two dozen ... a federal litigation involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), ... Liebhard LLP reports. , A Case List updated ... class of Type 2 diabetes medications referred to as ... District Court, Southern District of California, where a federal ...
(Date:11/23/2014)... DC (PRWEB) November 23, 2014 “BlackVue” ... Tech Report , which features the latest and ... technology expert and reporter for NewsWatch, conducted the product ... are unique and powerful options in the car camera ... rising and it can be hard to find the ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Tips for using the full line of dermatologist ... The Theraplex Company, the,makers of a full line ... range of dry skin conditions, is launching its ... and advice for,healthy looking and beautiful skin. Four ...
... Schizophrenia emerges from an altered pattern of brain development, ... cause the brain to develop along a path that ... article to be published in Biological Psychiatry on March ... link to schizophrenia. , A prior genetic mapping study ...
... TotalLook MammoAdvantage(TM)Provides Enhanced Image Quality, Customization ... and Workflow Benefits to Mammography ... Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection ... announced the,availability of the TotalLook MammoAdvantage system which ...
... can used to diagnose severity of bipolar illness , , ... blood associated with mood disorders have been identified by ... finding may change the way bipolar illness is diagnosed ... 96 patients and found varying levels of the biomarkers ...
... renters told Apartments.com, during national heart, awareness month, ... of on-site fitness facilities offered ... The majority of renters lead a healthy,lifestyle by eating ... would also,prefer to step up their current workout routine ...
Cached Medicine News:Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4Health News:New genetic association with schizophrenia found by researchers 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 2Health News:iCAD Introduces Next-Generation TotalLook Film Digitizer 3Health News:Biomarkers for Mood May Alter Psychiatric Treatments 2Health News:National Survey Reveals Most Renters Want What They Do Not Have: On-Site Workout Facilities 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: